News

Just a summary of all the news articles that we could source from different places. A good way to make an investment decision is also to look at how actively the company is engaging with news sources to keep them in the news. In this day and age its critical to have a media presence.

Please consider a small donation if you think this website provides you with relevant information  

   
Date Title Source
2024-02-29 3:10:39 pm Mesoblast Limited (MESO) Q2 2024 Earnings Call Transcript SeekingAlpha
2024-02-29 12:41:7 pm Mesoblast First Half 2024 Earnings: EPS Beats Expectations, Revenues Lag Simply Wall St.
2024-02-28 2:57:0 pm Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023 GlobeNewswire
2024-02-26 4:0:0 am Mesoblast Financial Results and Corporate Update Webcast GlobeNewswire
2024-02-14 4:46:0 pm United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease GlobeNewswire
2024-01-30 6:13:0 pm Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023 GlobeNewswire
2024-01-19 8:30:0 am Mesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug Zacks
2024-01-18 3:36:0 pm United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease GlobeNewswire
2024-01-08 4:35:9 pm Mesoblast (ASX:MSB) investors are sitting on a loss of 88% if they invested three years ago Simply Wall St.
   

Please consider a small donation if you think this website provides you with relevant information